top of page

ARE PEPTIDES LEGAL IN 2026? WHAT THE FDA DID, WHAT IT DIDN'T, AND WHY "RESEARCH USE ONLY" IS A RED FLAG

Hartwater Wellness branded prescription multi-dose vial on a white background

Are peptides legal in 2026? Some are. For any one peptide, the answer depends on two things: whether federal law lets a pharmacy compound that ingredient, and whether it reaches you through a prescription and a licensed pharmacy. FDA-approved peptide drugs, such as semaglutide, are legal with a prescription. A compounded peptide is legal when a licensed pharmacy prepares it for a named patient from an ingredient that qualifies under federal compounding law. Several popular wellness peptides do not qualify yet, even after two FDA steps this year. Here is what changed, what did not, and how peptide therapy at a medical practice differs from a "research use only" vial bought online.


By Elaine Burris, APRN, FNP-C, Wellness Nurse Practitioner, Hartwater Wellness


Medically reviewed by Scott Bradley Burris, MD, Medical Director and board-certified anesthesiologist. Reviewed October 2026.


THE SHORT ANSWER


  • FDA-approved peptide drugs: legal with a prescription. Semaglutide and tirzepatide are two examples.

  • Compounded peptides: legal when a licensed pharmacy prepares them for a named patient from an ingredient federal law allows.

  • April 15, 2026: the FDA announced it would take 12 peptides, including BPC-157, off its list of ingredients that raise significant safety risks. That step did not authorize compounding them.

  • July 23 and 24, 2026: an FDA advisory committee recommended six peptides for the list of ingredients pharmacies may use. Its vote is advice. The FDA has not acted on it.

  • Still pending as of October 28, 2026: any proposed rule, and a temporary access policy sent to the White House for review on October 14.

  • "Research use only": FDA warning letters issued this year treat that label as no defense when the seller's own website points to human use.


ARE PEPTIDES LEGAL? HOW FEDERAL COMPOUNDING LAW DECIDES


Most wellness peptides are not FDA-approved drugs. They reach patients through compounding, in which a licensed pharmacist prepares a medication for an individual patient's prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act allows this only from bulk ingredients that meet one of three conditions:


  1. The ingredient has a United States Pharmacopeia monograph, and the pharmacy follows it.

  2. The ingredient is a component of an FDA-approved drug.

  3. The ingredient appears on the FDA's 503A bulks list, which the FDA builds through formal rulemaking.


While that list is being built, the FDA sorts nominated ingredients into three interim categories:


  • Category 1, under evaluation. The FDA has said it does not intend to take action against a 503A pharmacy that compounds with these ingredients when other conditions are met. NAD, the coenzyme in the infusion covered in our post on how long an NAD+ IV takes, is on this list.

  • Category 2, significant safety risks. The FDA may take enforcement action against pharmacies that compound with these.

  • Category 3, nominated without adequate support. These can be nominated again with better evidence.


An ingredient that meets none of the three conditions and sits in no category falls outside the FDA's interim policy, so a pharmacy that compounds with it has no safe harbor. That gap explains most of the confusion about peptides in 2026.


WHAT THE FDA DID IN 2026


The table lists each federal action on peptides this year, with what it means and what it does not mean.



THE APRIL DELISTING


On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2 because the groups that had nominated them withdrew their nominations. The removal took effect about a week later. The 12 include BPC-157, TB-500 (a fragment of thymosin beta-4), KPV, MOTS-c, Semax, Epitalon, and the injectable form of GHK-Cu.


None of the 12 moved into Category 1 or onto the bulks list. They left the safety-risk category without entering any category that covers compounding. The FDA's page summarizing its safety concerns about each of them is still posted. Many websites described the April change as legalization. The FDA record shows a procedural step that cleared the way for a formal review.


THE JULY ADVISORY VOTES


The FDA's Pharmacy Compounding Advisory Committee met July 23 and 24, 2026. By narrow margins, it recommended BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A bulks list. It voted against a seventh peptide, emideltide (DSIP). The FDA's own briefing document had recommended against adding BPC-157, citing gaps in how the ingredient is characterized and the potential for immune reactions to injected peptides.


Each peptide was reviewed for specific uses. BPC-157 was evaluated for ulcerative colitis, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis. A recommendation tied to those uses says nothing about recovery, longevity, or any other goal.


The committee advises, and the FDA decides. Adding an ingredient to the bulks list takes a proposed rule, a public comment period, and a final rule. As of October 28, 2026, no proposed rule had appeared in the Federal Register. The FDA has also said it will consult the committee on GHK-Cu before the end of February 2027.


WHAT IS STILL PENDING


On October 14, 2026, HHS and the FDA sent a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review. Its text has not been published. News reports describe a temporary policy under which the FDA would not pursue pharmacies that compound certain peptides. Until the FDA issues it, the policy has no effect. We will update this post when it does.


WHY "RESEARCH USE ONLY" IS A RED FLAG


Between March 31 and August 24, 2026, the FDA sent warning letters to 11 online peptide sellers. Each seller labeled its products for research, with phrases such as "not for human consumption." In each letter, the FDA found that the seller's own website showed the products were meant for people, and it classified them as unapproved new drugs. The letters cited product descriptions of effects in the body, dosing guides and calculators, and bacteriostatic water sold for mixing injections. One of the August letters went to a seller in Dallas.


Most of the products named were weight-loss peptides sold as copies of semaglutide, tirzepatide, and the investigational drug retatrutide. Semaglutide and tirzepatide are FDA-approved drugs at a pharmacy. In a research vial sold online, the FDA treats the same molecule as an unapproved new drug.


A research vial comes without the safeguards that make a prescription safe to inject:


  • No prescription and no patient. Nobody screened you, chose a dose, or planned follow-up labs.

  • No licensed pharmacy. Pharmacies that compound sterile injections work under the USP <797> sterile compounding standard and answer to a state board of pharmacy. A research supplier answers to neither.

  • No verified identity or purity. The FDA's July briefing on BPC-157 raised concerns about impurities and characterization in the ingredient itself. A vial from an unregulated source adds unknown handling on top of that.


A PRESCRIBED PEPTIDE VS A RESEARCH VIAL


A prescription peptide compounded by a licensed 503A pharmacy differs at every step. A licensed prescriber evaluates you and writes a prescription in your name. A pharmacy licensed by the Texas State Board of Pharmacy prepares it under USP standards, from an ingredient that has to qualify under federal law, and labels it for you. Your prescriber then follows your response with labs.


Compounded peptides are not FDA-approved, and the FDA has not evaluated them for safety or effectiveness. They are not generic versions of any brand-name drug. What a prescription adds is accountability: a named patient, a licensed prescriber, a licensed pharmacy, and a record of each.


PEPTIDE THERAPY AT HARTWATER WELLNESS


Every peptide we prescribe is compounded by licensed Texas 503A pharmacies in the Dallas-Fort Worth area, under a prescription from our team, with Scott Bradley Burris, MD overseeing every protocol. Peptides are one tool within the Nine Health Categories assessment every Hartwater Wellness patient completes. We use them where your labs and goals point to them. You cannot optimize what you have not measured, so care starts with a consultation and a baseline lab panel. Follow-up labs are typically at six weeks and then quarterly.


Federal rules on several peptides are still moving. When the FDA acts on any of the peptides above, we will review our menu with our compounding pharmacies and update this post.


Peptide therapy is $285 per month for a single peptide, $239 per month each for a bundle of two, and $215 per month each for a bundle of three. Hartwater Wellness is a cash-pay practice; HSA and FSA accepted.


FREQUENTLY ASKED QUESTIONS


Is BPC-157 legal in 2026?


BPC-157 is not an FDA-approved drug. In April 2026 the FDA removed it from Category 2 after its nominations were withdrawn. In July 2026 an advisory committee recommended adding it to the 503A bulks list, after reviewing it for ulcerative colitis. As of October 28, 2026, the FDA had not proposed a rule to add it to the list. It was not in Category 1.


Did the FDA make peptides legal in April 2026?


No. Removing 12 peptides from Category 2 took them off the FDA's list of significant safety risks. It did not place them in Category 1 or on the 503A bulks list, the two places that would cover compounding with these ingredients.


Are research peptides legal to buy?


The FDA's 2026 warning letters treat research-labeled peptides marketed for human use as unapproved new drugs, which cannot legally be sold for that purpose. Whatever the label says, a research vial has no prescription, no licensed pharmacy, and no quality standard behind it.


Are compounded peptides FDA-approved?


No. Compounded medications are not FDA-approved, and the FDA has not evaluated them for safety or effectiveness. They are prepared by licensed pharmacies, under USP standards, for an individual patient's prescription.


How much does peptide therapy cost in McKinney?


At Hartwater Wellness, peptide therapy is $285 per month for one peptide, $239 per month each for two, and $215 per month each for three. Hartwater Wellness is a cash-pay practice; HSA and FSA accepted.


SCHEDULE A CONSULTATION


If you have been weighing peptides and want a clear answer on what fits your goals and your labs, a consultation is the place to start. Hartwater Wellness is a physician-led practice at 7200 West University Drive, Suite 170, in McKinney, serving Frisco, Allen, Prosper, Plano, Celina, and Collin County. Schedule online or call (469) 678-8748.


SOURCES


bottom of page